24/7 Market News Snapshot 25 June, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

June 25, 2025

DENVER, Colo., 25 June, 2025 (www.247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
PLUS THERAPEUTICS, Inc. (PSTV), a clinical-stage pharmaceutical company dedicated to advancing targeted radiotherapeutics for challenging central nervous system (CNS) cancers, is experiencing a significant surge in stock market activity, trading at $0.313 during pre-market hours, reflecting an impressive increase of 67.38% from its last closing price of $0.187. With trading volume exceeding 50.51 million shares, this heightened interest underscores strong investor confidence in the company’s innovative therapies.

The momentum coincides with the recent clearance of PLUS THERAPEUTICS’ Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its pioneering therapy, REYOBIQ™ (Rhenium Re186 Obisbemeda). This novel treatment is specifically aimed at pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma—conditions that have long posed significant challenges due to limited effective treatment options.

In an initiative supported by a $3 million grant from the U.S. Department of Defense, the Phase 1/2a clinical trial—named the ReSPECT-PBC trial—aims to advance the standards of care for young patients facing aggressive brain tumors. Principal Investigator Dr. Ashley S. Plant expressed enthusiasm about studying REYOBIQ, highlighting its potential to deliver targeted beta radiation directly into tumor cells while sparing healthy brain tissue from damage. This approach employs convection-enhanced delivery (CED) as a means to overcome the complexities of treatment.

The trial, which seeks to enroll pediatric patients aged 6 to 21 years, will assess safety, tolerability, and determine the maximum tolerated dose (MTD) across both phases. Dr. Plant emphasized the critical nature of this research and the hope it offers to patients and families affected by these formidable cancers.

Marc Hedrick, M.D., President and CEO of Plus Therapeutics, reiterated the significance of REYOBIQ in providing new therapeutic options, aiming to improve outcomes in pediatric brain cancer treatment. As the company navigates this pivotal moment, it stands at the forefront of innovation while capturing substantial market interest.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.